Decipher — formerly GenomeDx Biosciences — will help Dendreon identify patients who are likely to respond to its prostate cancer therapy Provenge.
At the Precision Medicine World Conference, researchers from Sanford Health, Providence Health, and Israel's Maccabi discussed their genomics programs.
A study of the detection of potential adverse drug events or interactions found that using PGx information led to better prediction of serious issues, despite no significant change overall.
The test covers 27 genes in which variants are known to contribute to the effectiveness or safety of more than 360 medications for 30 conditions.
At a Thermo Fisher-sponsored workshop, two companies argued for the clinical utility of PGx LDTs as FDA prepared to issue a warning against unapproved tests.
The system relies on the use of scannable safety code cards containing patient data, along with a web portal and automated analysis tools that deliver customized diagnostic reports.
Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.
The German company validated the panel, which focuses on actionable results, in a 300-participant clinical study in collaboration with Robert-Bosch-Hospital in Stuttgart.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.